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Genetics constitute a crucial risk factor to schizophrenia. In the last decade, molecular
genetic research has produced novel findings, infusing optimism about discovering
the biological roots of schizophrenia. However, the complexity of the object of inquiry
makes it almost impossible for non-specialists in genetics (e.g., many clinicians and
researchers) to get a proper understanding and appreciation of the genetic findings and
their limitations. This study aims at facilitating such an understanding by providing a
brief overview of some of the central methods and findings in schizophrenia genetics,
from its historical origins to its current status, and also by addressing some limitations
and challenges that confront this field of research. In short, the genetic architecture
of schizophrenia has proven to be highly complex, heterogeneous and polygenic. The
disease risk is constituted by numerous common genetic variants of only very small
individual effect and by rare, highly penetrant genetic variants of larger effects. In spite
of recent advances in molecular genetics, our knowledge of the etiopathogenesis of
schizophrenia and the genotype-environment interactions remain limited.
Keywords: twin, adoption, linkage, candidate-gene, GWAS, CNVs, SNVs, self-disorders
INTRODUCTION
Despite a century of research, our knowledge of the etiology and pathogenetic unfolding of
schizophrenia remains scarce. A persistent scientific problem may have several overlapping
sources: it may be due to the intrinsic difficulty of the object of inquiry, to methodological or
technological inadequacies, or to a mistaken formulation of the research problem. As we shall see,
some of these sources have played a role in the history of research on schizophrenia genetics.
In the last decade, genetic research in schizophrenia has experienced a new dawn infused by
a regained optimism due to newly developed, far more advanced molecular, technological and
statistical methods. Given the rapid progress and intrinsic complexity of molecular genetic research
(reflected, e.g., in the technical language of many molecular genetic studies), it may be difficult for
outsiders to the field to grasp and appreciate the results from studies on schizophrenia genetics.
Since genes are considered the strongest risk factor for schizophrenia, some grasp of this complex
research domain is relevant in many clinical contexts.
The purpose of this article is to contribute to facilitate such an understanding by providing
an accessible overview of some of the central methods and findings in genetic research in
schizophrenia, from its historical origins to current status. In other words, we are not offering
a comprehensive review of the entire field but a brief overview that may provide the reader
with an initial orientation in the field. For this reason, we generally refrain from discussing the
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details of the manifold findings in especially molecular genetics.
Finally, we seek to articulate certain limitations and challenges
that tend to be deemphasized in this field of psychiatric
research.
MODELS OF GENETIC TRANSMISSION
It has for a long time been known that madness (and many
other human afflictions and characteristics) runs in families.
After Mendel’s discovery of the laws of monogenic transmission
of phenotypic traits, some of the earliest authors, describing
schizophrenia, assumed an inherited basis of schizophrenia risk
due to familial aggregation of the disease or its milder variants
(Bleuler and Jung, 1908). Themonogenic model of schizophrenia
was attractive for a variety of reasons, e.g., simplicity, a
hope of discovering a corresponding, simple pathophysiological
mechanism, and because it fitted into available theoretical
options (i.e., recessive, dominant, with varying penetrance). The
strictly monogenic theory was, however, quickly abandoned,
because it did not fit the empirical data (even with the
quantitative help of the concept of penetrance). Yet, the very
idea of one specific gene or, later, a few specific genes as being
etiologically necessary but not sufficient for the emergence of
schizophrenia survived until fairly recently. For example, Meehl
(1962) believed in a monogenic necessary gene, whose action
was modified by polygenic factors. Holzman (1989) proposed
the ‘‘latent trait model’’, suggesting that a dominant gene results
in a latent trait, a postulated neural deficit with potentially
pleiotropic manifestations (e.g., schizophrenia, schizotypy or
eye-movement disorder). Risch and Baron (1984) offered the
‘‘mixed model’’, claiming that a specific gene in combination
with a few oligogenes and a polygenic-multifactorial background
formed the genetic substrate. All these models have been
tried to fit, with varying degree of success, to the available
epidemiological data of schizophrenia. In this context, it
merits special attention that Gottesman and Shields (1967)
already proposed a polygenic model for schizophrenia. As
we shall see, research in molecular genetics documents that
schizophrenia is in fact best accounted for by complex, polygenic
model.
PRE-MOLECULAR GENETICS
In the first half of the 20th century, family studies demonstrated
that the rate of schizophrenia was higher in relatives of
patients with schizophrenia than in the general population
(Rüdin, 1916; Kahn, 1923; Schulz, 1932; Kallmann, 1938). Twin
studies documented that the concordance rate (i.e., both twins
suffering from schizophrenia) was elevated inmonozygotic (MZ)
twins compared to dizygotic (DZ) twins (Luxenburger, 1928;
Kallmann, 1946; Slater, 1953). These early twin studies were
later criticized for various methodological reasons (Rosenthal,
1959, 1962; vide infra). From the 1960s, improved twin
(Kringlen, 1967; Fischer, 1973) and adoption studies (Heston,
1966; Rosenthal et al., 1968; Kety et al., 1975; Tienari et al.,
1985) became crucial in determining the familial clustering and
concordance rates for schizophrenia. By indicating a strong
genetic component in the etiology of the illness, the studies
contributed to undermine the psychoanalytical hypothesis
of schizophrenic causation, claiming that schizophrenogenic
rearing was either a necessary or sufficient cause for developing
schizophrenia. The basic intuition behind the twin studies is
the following: given that MZ twins (sharing 100% of their
genes) and DZ twins (sharing 50% of their genes) share the
environment they are raised in, higher concordance rates in
MZ over DZ twins most likely result from genetic similarity.
Estimates of concordance rates for schizophrenia, based on
European twin studies from 1963 to 1987, show higher rates
for MZ (48%) than for DZ twins (17%; Gottesman, 1991),
and similar concordance rates were reported in European and
Japanese twin studies from 1992 to 1999—41%–65% for MZ
vs. 0%–28% for DZ twins (Cardno and Gottesman, 2000). A
meta-analysis (Sullivan et al., 2003) of twin studies estimates the
genetic liability to schizophrenia at 81% (95% CI, 73%–90%),
whereas shared environmental influences were estimated to be
11% (95% CI, 3%–19%). Finally, a few studies of children of
discordant MZ twins found a similar risk of schizophrenia
spectrum disorders in the children of the affected and unaffected
MZ twin (Gottesman and Bertelsen, 1989; Kringlen and Cramer,
1989), presumably indicating that unaffected MZ twins carry
silent (non-expressed) susceptibility genes for schizophrenia.
By contrast, for children of discordant DZ twins, the risk was
higher in the children of the affected DZ twin compared to the
children of the unaffected DZ twin (Gottesman and Bertelsen,
1989).
Adoption studies have documented that schizophrenia
spectrum disorders are more frequent in adopted-away children
of mothers with schizophrenia than in their control adoptees
(Heston, 1966; Rosenthal et al., 1968; Kety et al., 1975, 1994). A
cross-fostering study (Wender et al., 1974) found that children
of healthy parents, adopted by a family where one of the parents
later developed schizophrenia, did not have an increased risk of
developing schizophrenia. Other studies (Heston, 1966; Higgins,
1976) found that children of mothers with schizophrenia had
the same risk of developing the disorder independent of whether
they were raised by their biological mothers or by adopting
parents with no history of mental illness. A Finish adoption study
(Tienari et al., 1985, 2004) found that markedly dysfunctional
rearing environments (the adoptive families were initially
assessed and classified on a scale ranging from ‘‘1. healthy’’ to ‘‘5.
severely disturbed’’) predicted schizophrenia spectrum disorders
in adopted-away children of mothers with schizophrenia but not
in their genetically undisposed controls. Interestingly, similar
results were reported in the Danish High-Risk study (Mednick
et al., 1987), which found increased risk of schizophrenia in
children of mothers with schizophrenia, who were exposed to
unstable parenting or raised in public childcare institutions
(Parnas et al., 1985).
MOLECULAR GENETICS
The Human Genome Project (1990–2003) has been instrumental
in molecular genetic research in schizophrenia. The Human
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Genome Project was an international research effort to determine
the sequence of the human genome’s three billion base pairs
and to map all of its genes. At the dawn of molecular genetics
in the early 1980s, some researchers, though certainly not all,
believed that within a fairly limited period of time the availability
of DNA would reveal the biological causes of the disorder
(e.g., Andreasen, 1984), as jointly indicated by twin and adoption
studies.
The first DNA-based method was ‘‘linkage analysis’’,
which aimed at discovering genomic regions in samples of
affected extended or nuclear families and sibling pairs without
implicating a specific allelic variant. By examining the degree
of co-segregation of genetic markers and predefined phenotypic
traits (e.g., schizophrenia spectrum diagnosis), estimates of
linkage between the illness and genomic loci were obtained.
Linkage analysis is based on the observation that genetic markers,
which are located physically close on the same chromosome,
tend to be inherited together, i.e., they remain ‘‘linked’’ during
meiosis. Numerous linkage studies of schizophrenia have been
conducted, but positive findings have generally proved difficult
to replicate in subsequent studies (Risch and Merikangas, 1996).
In brief, results from meta-analyses (Badner and Gershon,
2002; Lewis et al., 2003; Ng et al., 2009) suggest that many
chromosomal regions may contain schizophrenia susceptibility
loci. Notably, these loci do not themselves confer risk but they
may harbor variants that do. These results also made it clear that
the power of the linkage design was too weak to address genomic
loci with small effects; the sample size requirement necessary
to detect linkage was simply practically unachievable (Risch
and Merikangas, 1996). Hence, other DNA-based methods were
required to key in on the genes potentially involved in the
etiology of schizophrenia.
The next wave of molecular genetic research in schizophrenia
employed the ‘‘candidate gene’’ approach, which, using a
case-control study design, explored if potential susceptibility
genes correlate with the disorder. In contrast to linkage
analysis, the candidate gene approach can detect genes with
small effect alleles provided that the sample size is adequate.
Candidate genes have usually been selected due to their
position (e.g., from findings in linkage analyses) or functionality
(e.g., genes coding for proteins related to dopamine or serotonin
neurotransmission). Today, more than 1000 candidate genes
have been tested (for details see http://www.szgene.org) but
despite identification of some genes with small effect alleles
(see e.g., Haraldsson et al., 2011), the overall results from the
candidate gene studies have been disappointing (Gejman et al.,
2011). Some of the most cited candidate genes are DISC1,
DTNBP1, NRG1 and COMT, but their potential pathogenetic
involvement in schizophrenia remains debated. The absence of
significant discoveries may have several reasons, e.g., difficulties
in replicating positive findings, inadequate statistical power,
and limited knowledge of the genes believed to be involved
in the pathophysiology of schizophrenia (which obviously
makes it difficult to select relevant candidate genes for
testing).
In contrast to the hypothesis-driven candidate gene approach
that typically could test only relatively few genetic markers
in delimited genomic loci in each study, the genome-wide
association studies (GWAS), which also often employ a
case-control study design, interrogate the genome purely
empirically (i.e., GWAS do not rely on any a priori selected
candidate genes) for associations between common genomic
variants or loci and the disorder. The identification and mapping
of millions of common single nucleotide polymorphisms
(SNPs), as facilitated by initiatives such as the International
HapMap Project and the 1000 Genomes Project (continued
by The International Genome Sample Resource), has been
instrumental for the GWAS approach. GWAS are based on
linkage disequilibrium, i.e., a non-random association of
alleles at two or more loci. Recent technological advances
such as microarrays and chips have made it possible to
quickly and inexpensively scan a million SNPs genome-
wide. The reasoning behind the GWAS approach is that
if specific allele variants are found more frequently in
patients than in their controls, then the allele variants may
be indicative of a genetic association. To minimize the risk
of Type I errors (i.e., false positives), most GWAS operate
with a stringent threshold of significance (p < 5 × 10−8).
Since 2007, schizophrenia GWAS have been published (for
details see http://www.genome.gov/gwastudies). Overall, the
studies have failed to support the findings from linkage
and candidate gene studies, but the GWAS have instead
identified a large number of new susceptibility loci of only
very small individual effects—and many of these genomic
loci have in fact been replicated in subsequent GWAS and
have reached meta-analytic genome-wide significance (see
e.g., Shi et al., 2009; Stefansson et al., 2009; Schizophrenia
Psychiatric Genome-Wide Association Study Consortium,
2011; Aberg et al., 2013; Ripke et al., 2013; Xiao and Li,
2016; Yu et al., 2016). One seminal study (Schizophrenia
Working Group of the Psychiatric Genomics Consortium,
2014) combined available schizophrenia GWAS samples into a
single analysis and successfully identified 128 independent
schizophrenia associations, spanning 108 risk loci of
genome-wide significance, 83 of which were novel findings.
For example, associations were found at dopamine receptor D2,
in several genes involved in glutamatergic neurotransmission
and synaptic plasticity, and in tissues with central immune
functions. The authors suggest that these results provide
some genetic support for the hypothesized links between
schizophrenia and dopamine and immune dysregulation,
respectively.
Furthermore, associations have repeatedly been found
between schizophrenia and genetic markers across the
extended Major Histocompatibility Complex (MHC) locus
on chromosome 6 (25–34 Mb), implicating the MHC locus as
strongest of the >100 loci of genome-wide significance (see
e.g., Shi et al., 2009; Stefansson et al., 2009; Schizophrenia
Psychiatric Genome-Wide Association Study Consortium, 2011;
Schizophrenia Working Group of the Psychiatric Genomics
Consortium, 2014). The MHC locus is known to harbor genes
with immune functions and attempts to link the locus to
schizophrenia date back to the 1970s (Gejman et al., 2011).
A recent study (Sekar et al., 2016) found that the association
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between schizophrenia and the MHC locus to a considerable
extent stems from many common, structurally distinct alleles
of the complement component 4 (C4), and these alleles
were moreover found to affect the expression of C4A and
C4B in the brain and to be associated with schizophrenia
in proportion to their effect on C4A expression. Finally,
it merits attention that several GWAS have found shared
genetic risk loci in schizophrenia and bipolar disorder (e.g.,
Moskvina et al., 2009; Schizophrenia Psychiatric Genome-Wide
Association Study Consortium, 2011; Cross-Disorder Group
of the Psychiatric Genomics Consortium, 2013; Sleiman et al.,
2013); we discuss these findings in the section on limitations and
challenges.
The rationale behind GWAS is the ‘‘common-disease
common-variants’’ hypothesis, which suggests that
schizophrenia is mainly associated with common genetic
variants (SNPs). As we have seen, large-scale GWAS have
identified more than 100 risk loci.
However, it merits attention that a seminal study
(International Schizophrenia Consortium et al., 2009)
demonstrated that a substantial polygenic component of
schizophrenia risk is in fact not to be found in a large number
of strongly associated loci but rather in thousands of common
alleles of only a very small effect that individually do not attain
significance. The predictive accuracy of polygenic risk scores
is likely to further improve as sample sizes continue to grow
(Dudbridge, 2013). Still, there is an increasing awareness that
common variants only explain a proportion of the heritability
of schizophrenia, which refers to the proportion of variance
between individuals that is accounted for by genetic factors.
Individually, most of these common alleles confer only relatively
small risk (typically odds ratios <1.2) but cumulatively they
have been estimated to explain between a quarter and half of the
variance in genetic liability (e.g., International Schizophrenia
Consortium et al., 2009; Lee et al., 2012; Ripke et al., 2013;
Arnedo et al., 2015). In other words, a proportion of the variance
in genetic liability is apparently not accounted for by common
genetic variants. Addressing this issues, the ‘‘common-disease
rare-variants’’ hypothesis (McClellan et al., 2007) proposes that
highly penetrant, rare (<1%) genetic variants, including copy
number variations (CNVs), single nucleotide variants (SNVs),
and small insertions and deletions (indels), contribute to the
genetic component of schizophrenia. The two hypotheses are
complementary to each other. In the following, we briefly address
some of the most significant rare genetic variants, which, in the
last few years, substantially have increased our understanding of
the spectrum of genetic risk variants.
First, there is now strong evidence that rare, de novo
(i.e., new, not inherited) or inherited CNVs, i.e., structural
genomic variants that consist primarily of duplication or
deletion, confer high risk for schizophrenia. CNVs range in
size from one kilobase (kb) to several megabase (Mb) pairs.
Several studies have found elevated levels of rare CNVs in
patients with schizophrenia compared to controls (International
Schizophrenia Consortium, 2008; Xu et al., 2008; International
Schizophrenia Consortium et al., 2009; Malhotra et al., 2011;
Szatkiewicz et al., 2014; Chang et al., 2016; Ruderfer et al., 2016).
For example, robust associations have been uncovered between
schizophrenia and rare, large (>100 kb) CNVs, including
deletions on chromosome 1q21.1, 3q29, 15q13.3 and 22q11.2,
and duplications on chromosome 16p11.2 and 16p13.11—the
odds ratios of these CNVs range from approximately 2 to 60
(Rees et al., 2015). Moreover, deletions of NRXN1 have been
substantially linked to schizophrenia (e.g., Kirov et al., 2009).
Second, exome sequencing, a technology that allows for
identification of DNA variants within the 1% protein-coding
regions or genes (exons) of the genome (the exome), has
enabled scans of genes for mutations at single-base resolution,
which previously could not be detected, i.e., SNVs and indels.
The rationale behind exome sequencing is that variations in
these sequences are likely to entail more severe consequences
than variations in the remaining 99% of the genome. Several
studies have now used exome sequencing to explore SNVs
and indels in schizophrenia. Some studies have reported a
slightly increased exome-wide level of rare and/or de novo
SNVs in patients with schizophrenia compared to controls
(Xu et al., 2012; McCarthy et al., 2014a, 2016) but this
finding has not been replicated in larger studies (Fromer
et al., 2014; Purcell et al., 2014). Interestingly, Fromer et al.
(2014) found de novo SNVs and indels to be significantly
enriched in glutamatergic postsynaptic proteins, comprising the
ARC (activity-regulated cytoskeleton-associated protein) and
N-methyl-D-aspartate receptor (NMDAR) postsynaptic protein
complexes, which previously have been linked to schizophrenia
in CNV studies (Glessner et al., 2010). Finally, Purcell et al.
(2014) used exome sequencing to explore rare SNVs and indels
in schizophrenia and found a polygenic burden of very rare
(<1/10,000), disruptive variants distributed across many genes
in a set of 2546 genes previously implicated in schizophrenia by
GWAS, and CNV and de novo SNV studies (see Richards et al.,
2016).
In sum, pre-molecular and molecular genetics have
demonstrated beyond doubt that genetics constitute a
strong risk factor for schizophrenia. In contrast to the initial
monogenic and oligogenic models of genetic transmission, there
is now compelling evidence that the genetic architecture
of schizophrenia is very complex, heterogeneous, and
polygenic—the disease risk is constituted by numerous common
genetic variants of only very small individual effects (e.g., SNPs)
and by uncommon, highly penetrant genetic variants of larger
effect (e.g., CNVs).
LIMITATIONS AND CHALLENGES
As any research question, pre-molecular and molecular genetic
studies in schizophrenia are based on certain assumptions and
confront various limitations and challenges that must be made
explicit if we are to properly appreciate the empirical findings.
In the following, we discuss what we believe are six of the most
important ones.
First, the classical twin design remains controversial and its
validity has regularly been called into question (e.g., Charney,
2012; Turkheimer and Harden, 2014). Although the intuition
behind the twin studies seems straightforward (vide supra),
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it is, in fact, not unproblematic. In order to take the higher
concordance rates in MZ than in DZ twins as evidence
for a genetic component, some fairly unlikely assumptions
are required, e.g., we must statistically hold the environment
constant, i.e., wemust assume that the environments experienced
byMZ andDZ twins do not differ in any way thatmay be relevant
for the development of schizophrenia; and we must assume
that genes and environment are both mutually independent and
jointly additive (inclusive) for the development of schizophrenia.
The problem with the classical twin design is that many, if not
most, behavioral traits seem to act quite similarly, i.e., definitely
heritable with some variance ascribable to the non-shared
environment and little to the shared environment. Notably, these
remarks do not undermine the identified concordance rates
for schizophrenia in MZ and DZ twins, but they do put into
perspective the problem of making inferences and estimations of
the size of the genetic component in schizophrenia on the basis
of the classical twin design. Although the classical twin design
does not play a major role in genetic studies today, estimates
of the genetic contribution to schizophrenia, based on previous
twin studies, are often stated as facts in many textbooks and
research articles on schizophrenia, and therefore we believe it is
still important to voice these concerns.
Second, a challenge confronting molecular genetic research is,
in our view, the apparent variability in the clinical manifestation
of schizophrenia and the absence of a biomarker to compensate
for the shortcomings in phenotypic demarcation. According to
Baron (2001), attempts to circumvent this problem have involved
dissecting schizophrenia into clinical subtypes aggregating in
families (e.g., periodic catatonia), replacing the phenotype
(schizophrenia) with symptom-based analysis (e.g., positive and
negative symptoms) or endophenotypes (e.g., impaired sensory
gating and ocular movement dysfunction), and blurring the
diagnostic boundaries between schizophrenia and other major
mental disorders (e.g., bipolar disorder). The elimination of
diagnostic boundaries has led to potentially interesting genetic
findings indicative of an overlap of genetic susceptibility loci
between schizophrenia and bipolar disorder (Moskvina et al.,
2009; Schizophrenia Psychiatric Genome-Wide Association
Study Consortium, 2011; Cross-Disorder Group of the
Psychiatric Genomics Consortium, 2013; Sleiman et al., 2013).
These results are somewhat surprising given that family studies
usually have found that these disorders do not co-aggregate
in families (Kendler et al., 1993; Maier et al., 1993). Yet, a
large, population-based study of approximately 75,000 affected
Swedish families with schizophrenia or bipolar disorder found a
co-aggregation in the families, providing some epidemiological
support for the hypothesis of an at least partially shared genetic
basis (Lichtenstein et al., 2009). Crucially, however, this study
was based on hospital discharge rather than research diagnoses,
and we may speculate if the apparent co-aggregation perhaps
could result from different diagnostic practices.
Third, it merits attention that the symptom-based analysis,
the blurring of diagnostic boundaries, the case-control design
of many GWAS, CNV and exome sequencing studies, and the
detection of shared genetic risk loci between schizophrenia,
bipolar disorder, and sometimes also autism is indicative of
a genetic vulnerability to mental disorders more broadly and
not to schizophrenia specifically (i.e., genetic pleiotropy). While
identifying shared genetic vulnerability is crucial in its own
right, keying in on what is specific for schizophrenia presents
an obvious target for contemporary and future molecular
genetic research. One way of keying in on what is specific
to schizophrenia is illustrated in a GWAS (Ruderfer et al.,
2014), where the authors explored the discriminability of
schizophrenia from bipolar disorder and found that no SNPs
reached genome-wide significance but, on the basis of computed
risk scores, the authors identified a polygenic signal capable
of discriminating schizophrenia from bipolar disorder. In this
context, it also merits attention that a study of relatives of
high-density schizophrenia families in Ireland found molecular
support for the concept of the schizophrenia spectrum and its
genetic basis (Bigdeli et al., 2014).
Fourth, another challenge concerns the implications of the
molecular genetic findings, i.e., how do we obtain scientific
knowledge of the effects of the, e.g., now >100 susceptibility loci
that have reached genome-wide significance and their possible
involvement in the etiology of schizophrenia? Is an empirical,
bottom-up approach, systematically eliciting the biological
functions related to each risk locus at all a negotiable road in
this case? The prospect of studying all identified loci, singly and
in potential mutual interactions, could turn into an infinite task.
Moreover, if common genetic variation implicates an intractable
amount of genes of only very small individual effect alleles, we
may find ourselves in a situation, where, as Goldstein (2009) put
it, ‘‘in pointing at everything, genetics would point at nothing’’.
Here, it seems that psychiatry may need assistance from systems
biology to convert a multitude of genes of small effect alleles into
a graspable and identifiable pathogenetic stream or field of study
(Sauer et al., 2007; McCarthy et al., 2014b).
Fifth, some authors have used the apparent overlap of
genetic susceptibility loci between schizophrenia and bipolar
disorder as a lever to criticize the clinical validity of the
Kraepelinian dichotomy (e.g., Owen et al., 2007; Lichtenstein
et al., 2009; Doherty and Owen, 2014). The perpetual rebirth of
the unitary view of psychosis is perhaps its clearest manifestation.
Another expression of the dissatisfaction with the current
psychiatric classification and the lack of etiological progress
is found in the Research Domain Criteria (RDoC), which
ultimately seeks to found psychiatric nosology on advances
in genetics, neuroscience, behavioral sciences, etc., i.e., by
disregarding the diagnostic categories of DSM-5 (American
Psychiatric Association, 2013) and ICD-10 (World Health
Organization, 1992). More generally, this criticism raises a
crucial question, viz. what defines a mental disorder? Should
we begin to understand psychosis on the basis of specific
genetic profiles or on the basis of clinical phenotypes? Opting
for a genetically (and biologically) informed remodeling of
psychiatric nosology (e.g., as described by Insel and Cuthbert,
2015), founded upon i.a. our limited knowledge of certain
susceptibility loci’s potential involvement in the etiology of
various mental disorders, appears self-defeating for a number of
diagnostic, therapeutic and epistemological reasons. In our view,
no diagnostic classification in psychiatry can remain indifferent
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to the relevant clinical phenotypes, i.e., the patients’ suffering,
experience and existence.
The final issue that we raise here is nosological and
psychopathological in nature and it offers another perspective
on how to key in on what is specific for schizophrenia, which
also has relevance for genetic research. In this context, it
merits attention that there are many schizophrenia definitions
(Jansson and Parnas, 2007; Kendler, 2016) and most of these
describe a relatively unspecific psychotic ‘‘end product’’ far
away from the fundamental neurophysiological disturbances
that assumingly are closer to the genetic basis of the disorder.
In other words, psychiatric nosology carves phenotypes that
have implications for research, and it is possible that the
reification of the schizophrenia phenotype, which occurred with
the so-called ‘‘operational revolution’’ in psychiatry in DSM-III
(American Psychiatric Association, 1980), has in fact impeded
rather than fostered research progress in schizophrenia (Parnas
and Jansson, 2015). For example, the current schizophrenia
concept in DSM-5 and ICD-10 defines the disorder as a primarily
delusional-hallucinatory clinical phenotype—a definition that
is remarkably different from Bleuler’s original concept of
schizophrenia. Bleuler (1950) famously distinguished between
‘‘fundamental’’ and ‘‘accessory’’ symptoms, arguing the former
are essential to schizophrenia, whereas the latter are not. On
his account, delusions and hallucinations were considered as
accessory symptoms—these symptoms are typically episodic in
nature, they can be entirely absent, and they may also be found
in other disorders. By contrast, the fundamental symptoms
exhibit a trait-like quality—‘‘[they] are present in every case
and at every period of the illness’’ (Bleuler, 1950, p. 13).
The fundamental symptoms include disturbances of association
(formal thought disorders), ambivalence, autism and experiential
ego-disorders, etc. Keenly aware of the poly-symptomatology of
schizophrenia, Bleuler argued that the decisive diagnostic factor,
separating schizophrenia from manic or depressive psychosis, is
the presence of fundamental symptoms (Bleuler, 1950, p. 304).
With the exception of severe forms of formal thought disorders,
Bleuler’s fundamental symptoms and thus the core, trait-
phenotypic features of schizophrenia were ignored in DSM-III
and subsequent editions of the DSM as well as in ICD-10.
The theoretical and empirical research on anomalous
self-experiences (‘‘self-disorders’’) can to some extent be
seen as a return to and a systematic succession of a
Bleulerian approach to psychopathology, i.e., the research
focus is once more directed towards certain specific, non-
psychotic, trait-like features of schizophrenia. However, where
Bleuler’s (1950) fundamental symptoms largely were expressive
features (signs), observable by the clinician, research on
self-disorders elicits certain subjectively lived experiential
anomalies (symptoms). For clinical descriptions of self-disorders
in schizophrenia spectrum disorders, see Parnas and Handest
(2003), Parnas et al. (2005a), Henriksen and Parnas (2012), and
Henriksen and Nordgaard (2016). During the last two decades,
empirical research on self-disorders consistently demonstrate: (i)
that self-disorders hyper-aggregate in schizophrenia spectrum
disorders but not in other mental disorders, including bipolar
disorder (Parnas et al., 2003; Parnas et al., 2005b; Raballo et al.,
2011; Haug et al., 2012; Raballo and Parnas, 2012; Nordgaard
and Parnas, 2014), (ii) that self-disorders occur in genetically
high-risk individuals (Raballo and Parnas, 2011), (iii) that
self-disorders are temporarily stable over a 5-year period
(Nordgaard et al., 2017); and finally (iv) prospective studies
indicate that self-disorders predict transition to psychosis in
an Ultra-High Risk for psychosis sample (Nelson et al., 2012)
and that high baseline scores of self-disorders predict later
transition to a schizophrenia spectrum diagnosis (Parnas et al.,
2011, 2016)—for a review see Parnas and Henriksen (2014).
Recently, self-disorders have been empirically explored as an
intermediate phenotype of schizophrenia. Especially, discovering
the neurophysiological correlates of self-disorders is already
a topic of intense research. Several studies now point to a
disturbance of emotional motor resonance and multisensory
integration impairment as body-level correlates of self-disorders
(e.g., Sestito et al., 2013, 2015a,b, 2017; Ebisch and Gallese, 2015).
These studies show the potential of applying self-disorders as a
target phenotype for neurobiological and also genetic research in
schizophrenia.
CONCLUSION
Pre-molecular and molecular genetic studies have demonstrated
that genetics form a strong risk factor for schizophrenia.
Many findings from schizophrenia GWAS have been replicated
and several of these findings have reached meta-analytic
genome-wide significance. The robust associations between
schizophrenia and the >100 susceptibility loci, the identified
CNVs and SNVs, respectively, seem promising on a number of
scores. Also, the importance of the thousands of common alleles
of only a very small effect, which do not individually achieve
significance but which collectively form a substantial polygenic
component of schizophrenia risk, should not be underestimated.
Hopefully, these results will pave the way to truly novel,
actionable, therapeutic knowledge. However, we should not fail
to also notice: (i) that associations between common (SNPs) or
uncommon (CNVs, SNVs) genetic variants and schizophrenia,
though statistical facts, are not necessarily indexes of causal
pathways; and (ii) that many of the discovered associations are,
in fact, non-specific to schizophrenia but indicative of a genetic
vulnerability to several mental disorders. Overall, the details
of the etiopathogenesis of schizophrenia and the genotype-
environment interactions remain to large extent unknown, and
therefore caution is still warranted when drawing conclusions
about the size of the genetic contribution in the etiology of the
disorder.
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